Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis

World Psychiatry

Volumn 15, Issue 2, 2016, Pages 166-174

  Vancampfort, Davy ^a   Correll, Christoph U ^b,c   Galling, Britta ^b   Probst, Michel ^a   De Hert, Marc ^a   Ward, Philip B ^d   Rosenbaum, Simon ^d   Gaughran, Fiona ^e   Lally, John ^e   Stubbs, Brendon ^e,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antipsychotics; bipolar disorder; Diabetes mellitus; major depressive disorder; schizophrenia; severe mental illness

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOZAPINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; BIPOLAR DISORDER; GEOGRAPHIC DISTRIBUTION; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SELF REPORT; SEX RATIO; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84973137860     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20309     Document Type: Article

References (49)

1. Chesney E, Goodwin GM, Fazel S., Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13: 153-60.
2. Reininghaus U, Dutta R, Dazzan P, et al., Mortality in schizophrenia and other psychoses: a 10-year follow-up of the AESOP first-episode cohort. Schizophr Bull 2015; 41: 664-73.
3. Chang CK, Hayes RD, Perera G, et al., Life expectancy at birth for people with serious mental illness from a secondary mental health care case register in London, UK. PLoS One 2011; 6: e19590.
4. Lawrence D, Hancock KJ, Kisely S., The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013; 346: f2539.
5. Saha S, Chant D, McGrath J., A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 2007; 64: 1123-31.
6. Hoang U, Goldacre MJ, Stewart R., Avoidable mortality in people with schizophrenia or bipolar disorder in England. Acta Psychiatr Scand 2013; 127: 195-201.
7. De Hert M, Correll CU, Bobes J, et al., Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
8. Mitchell AJ, Lord O., Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. J Psychopharmacol 2010; 24 (Suppl. 4): 69-80.
9. Mitchell AJ, Lord O, Malone D., Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. Br J Psychiatry 2012; 201: 435-43.
10. Mitchell AJ, Malone D, Doebbeling CC., Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry 2009; 194: 491-9.
11. De Hert M, Vancampfort D, Correll CU, et al., Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199: 99-105.
12. Mitchell AJ, Delaffon V, Vancampfort D, et al., Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012; 42: 125-47.
13. Sarwar N, Gao P, Seshasai SR, et al., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
14. Murray CJ, Vos T, Lozano R, et al., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.
15. Grundy SM, Benjamin IJ, Burke GL, et al., Diabetes and cardiovascular disease: statement for health professionals from the American Heart Association. Circulation 1999; 100: 1134-46.
16. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, 1999.
17. Vancampfort D, Wampers M, Mitchell AJ, et al., A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013; 12: 240-50.
18. Stubbs B, Vancampfort D, De Hert M, et al., The prevalence and predictors of type 2 diabetes in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015; 132: 144-57.
19. Vancampfort D, Mitchell AJ, De Hert M, et al., Prevalence and predictors of type 2 diabetes in people with bipolar disorder: a systematic review and meta-analysis. J Clin Psychiatry 2015; 76: 1490-9.
20. Vancampfort D, Mitchell AJ, De Hert M, et al., Type 2 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and predictors. Depress Anxiety 2015; 32: 763-73.
21. Stroup DF, Berlin JA, Morton SC, et al., Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
22. Moher D, Liberati A, Tetzlaff J, et al., The PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA Statement. PLoS Med 2009; 6: e1000097.
23. Egger M, Davey SG, Schneider M, et al., Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
24. Begg CB, Mazumdar M., Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
25. Duval S, Tweedie R., A non-parametric 'trim and fill' method for assessing publication bias in meta-analysis. J Am Stat Assoc 2000; 95: 89-98.
26. Correll CU, Detraux J, De Lepeleire J, et al., Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14: 119-36.
27. Vancampfort D, Probst M, Knapen J, et al., Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res 2012; 200: 73-8.
28. Vancampfort D, De Hert M, Sweers K, et al., Diabetes, physical activity participation and exercise capacity in patients with schizophrenia. Psychiatry Clin Neurosci 2013; 67: 451-6.
29. Ellingrod VL, Taylor SF, Dalack G, et al., Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 2012; 32: 261-5.
30. International Diabetes Federation. IDF diabetes atlas. Sixth edition update. Brussels: International Diabetes Federation, 2014.
31. Hammerman A, Dreiher J, Klang SH, et al., Antipsychotics and diabetes: an age-related association. Ann Pharmacother 2008; 42: 1316-22.
32. Gardner-Sood P, Lally J, Smith S, et al., Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med 2015; 45: 2619-29.
33. Vancampfort D, Stubbs B, Mitchell AJ, et al., Risk of metabolic syndrome and its components in people with schizophrenia, bipolar and major depressive disorders: a large scale meta-analysis of 198 studies. World Psychiatry 2015; 14: 339-47.
34. Nielsen J, Skadhede S, Correll CU., Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010; 35: 1997-2004.
35. Kessing LV, Thomsen AF, Mogensen UB, et al., Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197: 266-71.
36. De Hert M, Dekker JM, Wood D, et al., Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24: 412-24.
37. McIntyre RS, Alsuwaidan M, Goldstein BI, et al., The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry 2012; 24: 69-81.
38. Vancampfort D, De Hert M, Skjerven LH, et al., International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia. Disabil Rehabil 2012; 34: 1-12.
39. Gierisch JM, Nieuwsma JA, Bradford DW, et al., Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 2014; 75: 424-40.
40. De Hert M, Detraux J, van Winkel R, et al., Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8: 114-26.
41. De Hert M, Cohen D, Bobes J, et al., Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual levels. World Psychiatry 2011; 10: 138-51.
42. Holt RI., The prevention of diabetes and cardiovascular disease in people with schizophrenia. Acta Psychiatr Scand 2015; 132: 86-96.
43. Pillarella J, Higashi A, Alexander GC, et al., Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. Psychiatr Serv 2012; 63: 83-6.
44. Davidson JR., Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71 (Suppl. 1): e04.
45. Hennings JM, Schaaf L, Fulda S., Glucose metabolism and antidepressant medication. Curr Pharm Des 2012; 18: 5900-19.
46. Mojtabai R., Antidepressant use and glycemic control. Psychopharmacologia 2013; 227: 467-77.
47. Lamers F, Vogelzangs N, Merikangas KR, et al., Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry 2013; 18: 692-9.
48. Manu P, Correll CU, Wampers M, et al., Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry 2014; 13: 189-92.
49. Correll CU, Joffe BI, Rosen LM, et al., Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry 2015; 14: 55-62.